Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials and Methods:The medical charts of treatment-na...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2023-02-01
|
| Series: | Türk Oftalmoloji Dergisi |
| Subjects: | |
| Online Access: |
http://www.oftalmoloji.org/archives/archive-detail/article-preview/ranibizumab-or-aflibercept-monotherapies-in-treatm/58682
|
| _version_ | 1797894365790601216 |
|---|---|
| author | Mahmut Kaya Taylan Öztürk Nilüfer Koçak Betül Akbulut Yağcı Ferdane Ataş Süleyman Kaynak |
| author_facet | Mahmut Kaya Taylan Öztürk Nilüfer Koçak Betül Akbulut Yağcı Ferdane Ataş Süleyman Kaynak |
| author_sort | Mahmut Kaya |
| collection | DOAJ |
| description | Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials and Methods:The medical charts of treatment-naive patients with center-involved DME retrieved from our institutional database were reviewed in this retrospective cohort study. A total of 512 treatment-naive eyes with DME underwent either ranibizumab (Group I; 308 eyes) or aflibercept (Group II; 204 eyes) monotherapy and 462 patients were included. The primary outcome was visual gain over 12 months.Results:The mean number of intravitreal injections within the first year was 4.34±1.83 and 4.39±2.12 in Group I and II, respectively (p=0.260). The mean best corrected visual acuity (BCVA) improvement at 12 months was +5.7 and +6.5 ETDRS letters in Group I and II, respectively (p=0.321). However, among eyes with a BCVA score less than 69 ETDRS letters (54% of the study population), visual gain was more prominent in Group II (+15.2 vs. +12.1 ETDRS letters; p<0.001). Statistically significant decreases in central foveal thickness were observed with both ranibizumab and aflibercept monotherapy (p<0.001), with no significant difference between the groups. (p=0.148).Conclusions:No statistically significant difference was found in visual outcomes at 12-month follow-up between ranibizumab and aflibercept monotherapies using a PRN protocol, although there was a tendency toward slightly better functional and anatomic prognosis in the aflibercept arm. |
| first_indexed | 2024-04-10T07:07:49Z |
| format | Article |
| id | doaj.art-ea62083d572942ec817a66d58e095427 |
| institution | Directory Open Access Journal |
| issn | 1300-0659 2147-2661 |
| language | English |
| last_indexed | 2024-04-10T07:07:49Z |
| publishDate | 2023-02-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Oftalmoloji Dergisi |
| spelling | doaj.art-ea62083d572942ec817a66d58e0954272023-02-27T05:53:27ZengGalenos YayineviTürk Oftalmoloji Dergisi1300-06592147-26612023-02-01531303610.4274/tjo.galenos.2022.3822713049054Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life ExperienceMahmut Kaya0Taylan Öztürk1Nilüfer Koçak2Betül Akbulut Yağcı3Ferdane Ataş4Süleyman Kaynak5 Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Dokuz Eylül Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials and Methods:The medical charts of treatment-naive patients with center-involved DME retrieved from our institutional database were reviewed in this retrospective cohort study. A total of 512 treatment-naive eyes with DME underwent either ranibizumab (Group I; 308 eyes) or aflibercept (Group II; 204 eyes) monotherapy and 462 patients were included. The primary outcome was visual gain over 12 months.Results:The mean number of intravitreal injections within the first year was 4.34±1.83 and 4.39±2.12 in Group I and II, respectively (p=0.260). The mean best corrected visual acuity (BCVA) improvement at 12 months was +5.7 and +6.5 ETDRS letters in Group I and II, respectively (p=0.321). However, among eyes with a BCVA score less than 69 ETDRS letters (54% of the study population), visual gain was more prominent in Group II (+15.2 vs. +12.1 ETDRS letters; p<0.001). Statistically significant decreases in central foveal thickness were observed with both ranibizumab and aflibercept monotherapy (p<0.001), with no significant difference between the groups. (p=0.148).Conclusions:No statistically significant difference was found in visual outcomes at 12-month follow-up between ranibizumab and aflibercept monotherapies using a PRN protocol, although there was a tendency toward slightly better functional and anatomic prognosis in the aflibercept arm. http://www.oftalmoloji.org/archives/archive-detail/article-preview/ranibizumab-or-aflibercept-monotherapies-in-treatm/58682 afliberceptdiabetic macular edemapro re nata protocolranibizumab |
| spellingShingle | Mahmut Kaya Taylan Öztürk Nilüfer Koçak Betül Akbulut Yağcı Ferdane Ataş Süleyman Kaynak Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience Türk Oftalmoloji Dergisi aflibercept diabetic macular edema pro re nata protocol ranibizumab |
| title | Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience |
| title_full | Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience |
| title_fullStr | Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience |
| title_full_unstemmed | Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience |
| title_short | Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience |
| title_sort | ranibizumab or aflibercept monotherapies in treatment naive eyes with diabetic macular edema a head to head comparison in real life experience |
| topic | aflibercept diabetic macular edema pro re nata protocol ranibizumab |
| url |
http://www.oftalmoloji.org/archives/archive-detail/article-preview/ranibizumab-or-aflibercept-monotherapies-in-treatm/58682
|
| work_keys_str_mv | AT mahmutkaya ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience AT taylanozturk ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience AT niluferkocak ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience AT betulakbulutyagcı ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience AT ferdaneatas ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience AT suleymankaynak ranibizumaborafliberceptmonotherapiesintreatmentnaiveeyeswithdiabeticmacularedemaaheadtoheadcomparisoninreallifeexperience |